[Pyr1]-Apelin-13

SKU: orb1296690

Description

[Pyr1]-Apelin-13

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 217082-60-5
• MW: 1533.8
• Purity: 100.00%
• Formula: C₆₉H₁₀₈N₂₂O₁₆S
• SMILES: CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC[C@@H]1CCCN1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O
• Target: Apelin receptor
• Solubility: H2O:125 mg/mL (81.5 mM)

Bioactivity

• In Vivo:
  In a study involving a mouse model of pressure-overload induced heart failure, nanocarriers containing [Pyr1]-apelin-13 demonstrated a prolonged effect in preventing cardiac dysfunction, highlighting its potential therapeutic benefits. Additionally, [Pyr1] apelin-13 at doses of 1 and 5 μg was found to enhance locomotor activity, alleviate pain symptoms, decrease cavity size, and reduce caspase-3 levels in rats, indicating its analgesic and anti-inflammatory properties. Furthermore, the compound significantly increased thermal paw withdrawal latency and, at a 5 μg dose, notably improved paw withdrawal threshold in comparison to spinal cord injury (SCI) animals from the second week post-SCI, suggesting its effectiveness in pain management and functional recovery post-SCI.
• In Vitro:
  Encapsulation of [Pyr1]-apelin-13 in lipoPEG particles (lipoPEG-PA13) enables sustained and extended drug release in both in vitro and in vivo conditions.

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Apelin receptor, Apelinreceptor, [pGlu1]-Apelin-13, [Pyr1] Apelin 13, [Pyr1]Apelin13, [Pyr-1]-Apelin-13, [Pyr1]-Apelin-13, inhibit, Inhibitor, endogenous apelin

Compound Identifiers

PubChem CID

137699157

Z Hajimashhadi, F Imani, F Nasirinezhad Intrathecal Administration of [Pyr1] apelin-13 Improves Functional Recovery in Rat Via Reducing Astrocytic Induced Inflammation in Ventral and Dorsal Spinal Cord International Journal of Peptide Research and Therapeutics, (2025)

PubMed: